Atlas Trials

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Clinical trial NCT02901548 · TERMINATED

Trial details

NCT number
NCT02901548
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma in Situ of BladderBladder Cancer
Start date
2017-02-16
Primary completion
2020-07-24
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.